IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones.

德克萨斯州欧文市——（商业新闻短讯）——biote Corp.（纳斯达克：BTMD）（“biote”或“公司”）是一家通过提供个性化激素优化和治疗健康的预防保健领先解决方案提供商，今天宣布了一项最终协议，收购F.H.Investments，Inc.，d/b/a Asteria health，一家私营的503B复合生物相同激素制造商。

The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states..

该公司在阿拉巴马州伯明翰经营一家FDA注册的503B外包设施，目前在美国多个州支持Biote认证从业人员和Biote合作诊所。。

Through this transaction, Biote is strengthening the Company’s control over its supply chain and enhancing efficiency. Additionally, Asteria Health provides Biote with expertise in 503B manufacturing, enabling longer-term development of innovative therapeutic wellness products. Biote plans to phase in manufacturing from Asteria Health.

通过此次交易，Biote正在加强公司对其供应链的控制并提高效率。此外，Asteria Health为Biote提供503B制造方面的专业知识，从而能够长期开发创新的治疗保健产品。Biote计划逐步从Asteria Health生产。

Because Asteria Health is currently a supplier to Biote-certified practitioners, there is expected to be minimal near-term revenue impact to Biote from the transaction..

由于Asteria Health目前是Biote认证从业者的供应商，因此该交易对Biote的短期收入影响预计很小。。

Terry Weber, Biote Chief Executive Officer, commented, “We are pleased to announce an agreement to acquire Asteria Health, and we welcome their talented and dedicated team to Biote. This strategic transaction expands and strengthens Biote’s capabilities by enabling the vertical integration of our manufacturing and providing direct control over our pharmacokinetic research efforts.

Biote首席执行官特里·韦伯（Terry Weber）评论道：“我们很高兴宣布收购Asteria Health的协议，我们欢迎他们富有天赋和敬业精神的团队加入Biote。这项战略性交易通过实现我们制造业的垂直整合和对我们的药代动力学研究工作的直接控制，扩大并加强了Biote的能力。

As we insource manufacturing, we anticipate improvement to our margin profile. We also see a longer-term opportunity to leverage Asteria Health’s product development expertise to expand our offerings with therapeutic wellness products for Biote-certified practitioners.”.

随着我们对制造业的外包，我们预计利润状况会有所改善。我们还看到了一个长期的机会，可以利用Asteria Health的产品开发专业知识，为Biote认证的从业者扩展我们的治疗保健产品。”。

Bill Fixler, PharmD, President of Asteria Health, said, “Asteria Health is proud of our longstanding relationship with Biote, an established leader in hormone replacement education and training. Both Asteria Health and Biote share an unwavering commitment to promoting patient health and evidence-based therapeutic wellness, and we are delighted to join Biote to further this mission.”.

Asteria Health总裁Bill Fixler表示：“Asteria Health为我们与Biote的长期关系感到骄傲，Biote是激素替代教育和培训领域的公认领导者。Asteria Health和Biote都坚定不移地致力于促进患者健康和循证治疗健康，我们很高兴加入Biote来推进这一使命。”。

Dr. Fixler brings to Biote more than two decades of compounding and specialty pharmacy experience, with particular expertise in manufacturing compliance and product formulation.

Fixler博士为Biote带来了20多年的复合和专业药房经验，在生产合规性和产品配方方面具有特殊的专业知识。

Transaction Terms

交易条款

Under the terms of the acquisition agreement, the purchase price is $8.5 million, subject to customary adjustments. Asteria Health shareholders are eligible to receive up to an additional $500,000 if certain production metrics are achieved by April 1, 2024. Biote will fund the transaction with cash from its balance sheet..

根据收购协议的条款，购买价格为850万美元，但须按惯例进行调整。如果在2024年4月1日之前达到某些生产指标，Asteria Health股东有资格获得额外的50万美元。Biote将用其资产负债表中的现金为交易提供资金。。

The acquisition is subject to customary closing conditions, with closing anticipated to occur in the first quarter of 2024.

收购受惯例交割条件的约束，预计交割时间为2024年第一季度。

Truist Securities served as financial advisor to Biote.

Truist Securities担任Biote的财务顾问。

About Biote

关于Biote

Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners..

Biote通过Biote认证的医疗提供商提供的创新、个性化激素优化和治疗性健康解决方案，正在改变健康老龄化。Biote培训从业者识别和治疗衰老状况的早期指标，这是一个服务不足的全球市场，为患者提供负担得起的症状缓解，并推动从业者取得临床成功。。

Forward-Looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的某些前瞻性声明。一些前瞻性陈述可以通过使用前瞻性词语来识别。

Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements.

非历史性陈述，包括“可能”、“可以”、“应该”、“将会”、“估计”、“计划”、“项目”、“预测”、“打算”、“期望”、“希望”、“期望”、“相信”、“寻求”、“目标”、“继续”、“可能”、“可能”、“正在进行”、“潜在”、“预测”、“将会”等类似表达，旨在识别前瞻性陈述。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the potential that our acquisition of Asteria Health is not consummated; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strate.

前瞻性陈述是基于当前预期和假设的关于未来事件的预测、预测和其他陈述，因此会受到风险和不确定性的影响。许多因素可能导致实际结果或发展与此类前瞻性声明所表达或暗示的结果或发展存在重大差异，包括但不限于：我们收购Asteria Health的潜力尚未完成；我们的膳食补充剂成功地在诊所，从业者及其患者中获得了显着的市场认可；我们的客户依赖某些第三方来支持为处方者生产生物相同的激素；我们和我们的客户对某些地理区域的监管、经济、环境和竞争条件的敏感性；我们能够以我们预期的速度或根本不需要的速度增加从业人员和诊所对Biote方法的使用；我们发展业务的能力；我们在行业中面临的巨大竞争；战略收购的影响和我们增长战略的实施。